PRTO Proteon Therapeutics, Inc.

1.30
+0.00  (0%)
Previous Close 1.30
Open 1.30
Price To book 0.56
Market Cap 21.58M
Shares 16,603,000
Volume 100,828
Short Ratio 2.06
Av. Daily Volume 180,660

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 13, 2016 - primary endpoint not met.
Vonapanitase (PRT-201) PATENCY-1
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 3 enrollment to be completed 1Q 2018. Data due 1Q 2019.
Vonapanitase (PRT-201) PATENCY-2
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)

Latest News

  1. Proteon Therapeutics reports 1Q loss
  2. Proteon Therapeutics Announces First Quarter 2017 Financial Results
  3. Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase
  4. Proteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical Trial
  5. Proteon Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference May 4th
  6. Lifshitz & Miller LLP Announces Investigation of BRF S.A., Innoviva, Inc., Panera Bread Company, PRA Group, Inc., Proteon Therapeutics, Inc., tronc, Inc. and Vuzix Corporation
  7. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Proteon Therapeutics, Inc.
  8. Proteon CEO: New trial could be a path to market
  9. Proteon Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference March 22nd
  10. Proteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial
  11. These 5 Stocks Under $10 Could Make You a Lot of Money
  12. Failure in late clinical trial pummels Proteon Therapeutics stock
  13. Proteon Slips to 52-Week Low on Kidney Disease Study Data
  14. Proteon Therapeutics Craters on Missed Late-Stage Results
  15. Waltham biotech's shares tank after kidney disease drug flunks trial
  16. Proteon Therapeutics kidney drug fails key study